ClinicalTrials.gg
CompletedNCT00398086Updated Nov 22, 2019Results posted

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

A Phase 1/2 interventional study of Gemcitabine and Albumin-bound paclitaxel in Metastatic Pancreatic Cancer, sponsored by Celgene. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Enrollment
100th of 352
67 · median 37
Started
2006
with 25 others
Phase 1/2
38 of 369
3 open now
Registered
99th of 369
by date
Lead sponsor
5 of 369
Celgene

Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 100th largest by enrollment of the 352 interventional ones that give a count, is one of 26 that started in 2006, is one of 38 in phase 1/2, and was the 99th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.

Read the detailed description

Albumin-bound paclitaxel is a novel, solvent-free, albumin-bound, 130 nanometer particle form of paclitaxel designed to avoid the problems associated with solvents used in Taxol(Abraxane prescribing information 2005). Albumin has a number of properties that make it an attractive molecule to combine with paclitaxel. Albumin is a natural transporter of endogenous hydrophobic molecules such as water-insoluble vitamins and hormones (Vorum 1999)and albumin binding to the gp-60 receptor (albondin) initiates the caveolae-mediated endothelial transport of protein-bound and unbound plasma constituents (John et al 2003, Minshall et al 2003, Tiruppathi et al 1997).

This study consisted of a Phase 1 dose escalation phase, a Phase 2 treatment phase and a 24-month follow-up phase.

03

Conditions studied

  • Metastatic Pancreatic Cancer

Keywords

  • Metastatic Pancreatic Cancer, Abraxane, Gemcitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has or cytologically confirmed adenocarcinoma of the pancreas. Patients with islet cell neoplasms are excluded.
  • Male or non-pregnant and non-lactating female, and age greater or equal to 18.

    • If a female patient is of , as evidenced by regular menstrual periods, she must have a negative serum pregnancy test beta-human chorionic gonadotropin (B-hCG) documented within 72 hours of the first administration of study drug.
    • If sexually active, the patient must agree to use considered adequate and appropriate by the investigator.
  • Patient must have received no prior therapy for the treatment of metastatic disease. Prior treatment with 5-fluorouracil (5-FU) or gemcitabine administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed. If a patient received gemcitabine in the setting, tumor recurrence must have occurred at least 6 months after completing the last dose of gemcitabine.
  • Patient has the following blood counts at baseline

    • (ANC) equal or greater to 1.5 x 10\^9/L;
    • equal or greater to 100 x 10\^9/L
    • equal or greater to 9 g/dL.
    • Patient has the following blood chemistry levels at baseline:
    • (SGOT), Alanine aminotransferase (SGPT) equal or less than 2.5 x (ULN) is allowed
    • less than or equal to ULN
    • Serum creatinine within normal limits or calculated clearance equal or greater to 60 mL/min/1.73M\^2 patients with serum creatinine levels above the institutional normal value
  • Patient has no abnormalities in urinalysis results
  • Patient has acceptable coagulation status as indicated by a (PT) within normal limits (plus or minus 15%) and partial thromboplastin time (PTT) within normal limits (plus or minus 15%).
  • Patient has a performance status (KPS) greater or equal to 70 ( [ECOG] PS 0-1).
  • Patient has one or more metastatic tumors measurable by computed tomography (CT) scan.
  • Patient has been informed about the nature of study, and has agreed to participate in the study, and signed the form prior to participation in any study-related activities.

Exclusion criteria

Exclusion Criteria:

  • Patient has known unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no and stable in two scans at least 4 weeks apart).
  • Patient uses therapeutic coumadin for a history of pulmonary emboli and deep vein thrombosis (DVT).
  • Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  • Patient has known infection with (HIV), , .
  • Patient has undergone major surgery, other than diagnostic surgery i.e.-- done to obtain a for diagnosis without removal of an organ), with 4 weeks prior to Day 1 of treatment in this study.
  • Patient received radiotherapy, surgery, chemotherapy, or an therapy within 3 weeks prior to study entry weeks (6 weeks for nitrosureas or mitomycin C).
  • Patient has a history of allergy or to the study drug.
  • Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.
  • Patient is unwilling or unable to comply with study procedures.
  • Patient is enrolled in any other clinical protocol or investigational trial.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    100 mg/m^2

    Participants received albumin-bound paclitaxel 100 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.

    Drug: Gemcitabine · Drug: Albumin-bound paclitaxel

  • Experimental
    125 mg/m^2

    Participants received albumin-bound paclitaxel 125 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.

    Drug: Gemcitabine · Drug: Albumin-bound paclitaxel

  • Experimental
    150 mg/m^2

    Participants received albumin-bound paclitaxel 150 mg/m\^2 followed by gemcitabine 1000 mg/m\^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.

    Drug: Gemcitabine · Drug: Albumin-bound paclitaxel

Interventions

  • Administered by intravenous infusion over 30 minutes.

    Also known as: Gemzar®

  • Administered by intravenous infusion over 30 minutes.

    Also known as: ABI-007, ABRAXANE®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities

    A dose-limiting toxicity (DLT) is defined as one or more of the following toxicities related to study drug during Cycle 1, according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3: * Grade 4 neutropenia lasting \>3 days in the absence of growth factor support; * Grade 4 neutropenia associated with fever \>38.5°C; * Any other Grade 4 hematological toxicity; * Grade 3 thrombocytopenia with hemorrhage; * Grade 3 or 4 nausea, vomiting or diarrhea despite prophylaxis or treatment with an optimal anti-emetic or anti-diarrhea regimen; * Any other Grade 3 or higher non-hematological toxicity attributable to the study drug, excluding alopecia and fatigue.

    Time frame: Cycle 1 (Days 1-28)

Secondary outcomes

  1. Number of Participants With Adverse Events (AE)

    An AE was any untoward medical occurrence, not necessarily having a causal relationship with the patient's treatment, that began or worsened in grade after the start of study drug through 30 days after the last dose. A serious AE (SAE) is any untoward medical occurrence that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. Treatment-related AEs (TRAEs) include those assessed by the Investigator as possibly, probably, or definitely related to study treatment. Severity was graded according to the NCI CTCAE based on the following: Grade 1- Mild; Grade 2 -Moderate; Grade 3 - Severe; Grade 4 - Life-threatening or disabling; Grade 5 - Death related to AE.

    Time frame: Up to 25 months

  2. Percentage of Participants Who Achieved an Objective Confirmed Overall Response

    Overall Response is defined as the percent of participants who achieve an objective confirmed complete (CR) or partial response (PR). Response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, assessed by an Independent Radiological Reviewer. CR: The disappearance of all known disease and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. PR: At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation and no new non-target lesions and/or unequivocal progression of existing non-target lesions. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.

    Time frame: Up to approximately 4 years

  3. Percentage of Participants With Disease Control

    Disease control is defined as participants with Stable Disease for at least 16 weeks, or confirmed complete or partial overall response, based on RECIST guidelines and assessed by an Independent Radiological Reviewer. Stable disease is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for Progressive Disease, and no new non-target lesions or unequivocal progression of existing non-target lesions. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: Up to approximately 4 years

  4. Progression-free Survival

    Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first, assessed by an Independent Radiological Reviewer. Participants who do not have disease progression or have not died were censored at the last known time that the participant was progression free. Progression-free survival was summarized using Kaplan-Meier methods. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: Up to approximately 4 years

  5. Duration of Response

    Duration of response was assessed by progression-free survival for participants who achieved a confirmed Complete Response or Partial Response, assessed by an Independent Radiological Reviewer.

    Time frame: Up to approximately 4 years

  6. Overall Survival

    Overall survival was defined as the time from the date of first dose of study drug to the date of patient death from all causes. Participants who did not die were censored at the last known time the patient was alive. Patient survival was summarized using Kaplan-Meier methods.

    Time frame: Up to approximately 4 years

  7. Maximal Degree of Myelosuppression

    The maximal degree of myelosuppression was assessed by the overall nadir of absolute neutrophil count (ANC), white blood cell count and platelet count based on clinical laboratory measurements.

    Time frame: During the treatment phase, up to a maximum of 24 months.

  8. Maximal Degree of Anemia

    The maximal degree of anemia (and myelosuppression) was assessed by the overall (any time after first dose of study drug) nadir of hemoglobin levels based on clinical laboratory measurements.

    Time frame: During the treatment phase, up to a maximum of 24 months.

07

Results

Posted Aug 21, 2013

Participant flow

Enrollment was initiated in November 2006 and completed in September 2008. Sixty-seven patients were enrolled at four sites in the US.

Participant flow — Overall Study
Milestone100 mg/m^2125 mg/m^2150 mg/m^2
Started20443
Phase 1, dose escalation population2073
Completed11211
Not completed9232
Withdrew: Unacceptable toxicity282
Withdrew: Adverse event140
Withdrew: Physician decision140
Withdrew: Withdrawal by subject570

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities

A dose-limiting toxicity (DLT) is defined as one or more of the following toxicities related to study drug during Cycle 1, according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3: * Grade 4 neutropenia lasting \>3 days in the absence of growth factor support; * Grade 4 neutropenia associated with fever \>38.5°C; * Any other Grade 4 hematological toxicity; * Grade 3 thrombocytopenia with hemorrhage; * Grade 3 or 4 nausea, vomiting or diarrhea despite prophylaxis or treatment with an optimal anti-emetic or anti-diarrhea regimen; * Any other Grade 3 or higher non-hematological toxicity attributable to the study drug, excluding alopecia and fatigue.

Time frame:
Cycle 1 (Days 1-28)
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities
participants100 mg/m^2125 mg/m^2150 mg/m^2
Number of Participants With Dose-limiting Toxicities401
SecondaryNumber of Participants With Adverse Events (AE)

An AE was any untoward medical occurrence, not necessarily having a causal relationship with the patient's treatment, that began or worsened in grade after the start of study drug through 30 days after the last dose. A serious AE (SAE) is any untoward medical occurrence that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. Treatment-related AEs (TRAEs) include those assessed by the Investigator as possibly, probably, or definitely related to study treatment. Severity was graded according to the NCI CTCAE based on the following: Grade 1- Mild; Grade 2 -Moderate; Grade 3 - Severe; Grade 4 - Life-threatening or disabling; Grade 5 - Death related to AE.

Time frame:
Up to 25 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participants100 mg/m^2125 mg/m^2150 mg/m^2
Patients with at least 1 AE20443
At least 1 grade 3 or higher AE15423
At least 1 treatment-related AE18423
At least 1 treatment-related grade 3 to 5 AE11383
Patients with at least 1 SAE10241
Patients with at least 1 treatment-related SAE4121
At least 1 AE and drug permanently discontinued3122
At least 1 TRAE and drug permanently discontinued282
At least 1 dose reduction due to TRAE4101
At least 1 dose interruption due to AE100
At least 1 treatment-related AE dose interruption100
At least 1 treatment-emergent dose delay due to AE14273
At least 1 treatment-related dose delay due to AE13273
At least 1 AE resulting in death011
SecondaryPercentage of Participants Who Achieved an Objective Confirmed Overall Response

Overall Response is defined as the percent of participants who achieve an objective confirmed complete (CR) or partial response (PR). Response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, assessed by an Independent Radiological Reviewer. CR: The disappearance of all known disease and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. PR: At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation and no new non-target lesions and/or unequivocal progression of existing non-target lesions. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.

Time frame:
Up to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Objective Confirmed Overall Response
percentage of participants100 mg/m^2125 mg/m^2150 mg/m^2
Percentage of Participants Who Achieved an Objective Confirmed Overall Response25 (8.7 to 49.1)39 (24.2 to 53.0)0 (NA to NA)
SecondaryPercentage of Participants With Disease Control

Disease control is defined as participants with Stable Disease for at least 16 weeks, or confirmed complete or partial overall response, based on RECIST guidelines and assessed by an Independent Radiological Reviewer. Stable disease is defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for Progressive Disease, and no new non-target lesions or unequivocal progression of existing non-target lesions. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
Up to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control
percentage of participants100 mg/m^2125 mg/m^2150 mg/m^2
Percentage of Participants With Disease Control55 (33.2 to 76.8)55 (39.8 to 69.3)33 (0.8 to 90.6)
SecondaryProgression-free Survival

Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first, assessed by an Independent Radiological Reviewer. Participants who do not have disease progression or have not died were censored at the last known time that the participant was progression free. Progression-free survival was summarized using Kaplan-Meier methods. Progressive Disease is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
Up to approximately 4 years
Reported as:
Median · months
Progression-free Survival
months100 mg/m^2125 mg/m^2150 mg/m^2
Progression-free Survival6.1 (3.7 to NA)6.9 (4.8 to 9.2)1.6 (0.5 to 10.0)
SecondaryDuration of Response

Duration of response was assessed by progression-free survival for participants who achieved a confirmed Complete Response or Partial Response, assessed by an Independent Radiological Reviewer.

Time frame:
Up to approximately 4 years
Reported as:
Median · months
Duration of Response
months100 mg/m^2125 mg/m^2150 mg/m^2
Duration of ResponseNA (2.4 to NA)7.3 (5.5 to 21.9)—
SecondaryOverall Survival

Overall survival was defined as the time from the date of first dose of study drug to the date of patient death from all causes. Participants who did not die were censored at the last known time the patient was alive. Patient survival was summarized using Kaplan-Meier methods.

Time frame:
Up to approximately 4 years
Reported as:
Median · months
Overall Survival
months100 mg/m^2125 mg/m^2150 mg/m^2
Overall Survival9.3 (6.6 to 11.9)12.2 (8.9 to 17.9)6.1 (0.5 to 17.9)
SecondaryMaximal Degree of Myelosuppression

The maximal degree of myelosuppression was assessed by the overall nadir of absolute neutrophil count (ANC), white blood cell count and platelet count based on clinical laboratory measurements.

Time frame:
During the treatment phase, up to a maximum of 24 months.
Reported as:
Mean · x10^9/L
Maximal Degree of Myelosuppression
x10^9/L100 mg/m^2125 mg/m^2150 mg/m^2
Absolute neutrophil count1.38 ± 1.5410.96 ± 1.4460.47 ± 0.460
White blood cell count2.69 ± 1.7342.18 ± 1.8491.52 ± 1.484
Platelet count120.3 ± 79.0288.3 ± 62.1058.7 ± 48.64
SecondaryMaximal Degree of Anemia

The maximal degree of anemia (and myelosuppression) was assessed by the overall (any time after first dose of study drug) nadir of hemoglobin levels based on clinical laboratory measurements.

Time frame:
During the treatment phase, up to a maximum of 24 months.
Reported as:
Mean · g/L
Maximal Degree of Anemia
g/L100 mg/m^2125 mg/m^2150 mg/m^2
Maximal Degree of Anemia95.1 ± 12.8591.8 ± 10.4395.3 ± 15.37

Adverse events

Collected over Adverse events were collected up to 30 days after the last dose (a maximum of 25 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 mg/m^2—10/20 (50%)20/20 (100%)
125 mg/m^2—24/44 (54.5%)44/44 (100%)
150 mg/m^2—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
Event100 mg/m^2125 mg/m^2150 mg/m^2
SepsisInfections and infestations0/200/441/3
PainGeneral disorders2/200/440/3
DehydrationMetabolism and nutrition disorders2/203/440/3
PyrexiaGeneral disorders1/203/440/3
PneumoniaInfections and infestations1/202/440/3
Neutropenic sepsisInfections and infestations1/201/440/3
Urinary tract infectionInfections and infestations1/200/440/3
DiarrhoeaGastrointestinal disorders1/201/440/3
Duodenal obstructionGastrointestinal disorders1/200/440/3
NauseaGastrointestinal disorders1/200/440/3
Most frequent other events
Showing 10 of 191
Most frequent other events
Event100 mg/m^2125 mg/m^2150 mg/m^2
FatigueGeneral disorders15/2039/443/3
AlopeciaSkin and subcutaneous tissue disorders15/2035/441/3
AnaemiaBlood and lymphatic system disorders12/2030/442/3
LeukopeniaBlood and lymphatic system disorders4/2018/442/3
NeutropeniaBlood and lymphatic system disorders10/2025/442/3
ThrombocytopeniaBlood and lymphatic system disorders5/2026/442/3
Abdominal painGastrointestinal disorders7/2017/442/3
DiarrhoeaGastrointestinal disorders7/2023/442/3
NauseaGastrointestinal disorders8/2029/442/3
VomitingGastrointestinal disorders5/2020/442/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)100 mg/m^2125 mg/m^2150 mg/m^2Total
Median62.0 (30 to 86)61.5 (28 to 78)69.0 (53 to 72)62.0 (28 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)100 mg/m^2125 mg/m^2150 mg/m^2Total
Female925135
Male1119232
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)100 mg/m^2125 mg/m^2150 mg/m^2Total
Asian1102
Black, of African Heritage0202
White, Non-Hispanic, and Non-Latino1637154
White, Hispanic, or Latino2428
Other1001
Region of Enrollment
Region of Enrollment(participants)100 mg/m^2125 mg/m^2150 mg/m^2Total
United States2044367
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)100 mg/m^2125 mg/m^2150 mg/m^2Total
0 (Fully Active)922233
1 (Restrictive but Ambulatory)1122134
Histology of Primary Diagnosis: Adenocarcinoma
Histology of Primary Diagnosis: Adenocarcinoma(participants)100 mg/m^2125 mg/m^2150 mg/m^2Total
Number2044367
Time from First Documented Metastasis/Relapse to Study Entry
Time from First Documented Metastasis/Relapse to Study Entry(months)100 mg/m^2125 mg/m^2150 mg/m^2Total
Median0.8 (0 to 11)0.7 (0 to 13)0.3 (0 to 1)0.7 (0 to 13)
Current Site(s) of Metastasis/Relapse
Current Site(s) of Metastasis/Relapse(participants)100 mg/m^2125 mg/m^2150 mg/m^2Total
Skin/Soft Tissue0101
Supraclavicular Nodes0202
Axilla2002
Bone1304
Lung/Thoracic518124
Liver1133246
Abdomen/Peritoneum1637154
Pelvis1315
Other86014

1 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • University of Alabama at Birmingham Comprehensive Cancer Ctr
    Birmingham, Alabama, United States
  • Scottsdale Healthcare/Virginia Pipe Cancer Institute
    Scottsdale, Arizona 85258, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
    Baltimore, Maryland 35233, United States
  • Virigina Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • South Texas Oncology & Hematology
    San Antonio, Texas 78258, United States
09

References and documents

Publications

  • Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3. PubMed 21969517 ↗
  • Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Curtis Bay R, Ramanathan RK. 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Cancer Imaging. 2017 Aug 3;17(1):23. doi: 10.1186/s40644-017-0125-5. PubMed 28774338 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2006 to primary completion in Sep 2008, 22 months.

Results were first posted in Aug 2013, 4 years 11 months after primary completion.

Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 88. This study's 22 months is below that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2006
First posted
Nov 10, 2006
StartActual
Nov 1, 2006
Primary completionActual
Sep 1, 2008
CompletionActual
Dec 1, 2010
Results first posted
Aug 21, 2013
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00398086
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 10, 2006
Start date
Nov 1, 2006
Primary completion
Sep 1, 2008
Completion
Dec 1, 2010
Results posted
Aug 21, 2013
Last update
Nov 22, 2019

Study contacts

Daniel Von Hoff, MD
principal investigator · Scottsdale Clinical Research Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion